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Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the main curative 
 therapy for hematological malignancy such as leukemias, lymphomas, or multiple myelo-
mas and some other hematological disorders. In this therapy, cure of hematological 
diseases relies on graft-versus-malignancy effects by allogenic immune cells. However, 
severe posttransplant treatment-associated complications such as acute graft-versus-
host disease (aGvHD) and chronic graft-versus-host disease (cGvHD) limit this approach. 
Most research into GvHD has concentrated on the aGvHD, while the more complex and 
multifaceted chronic form has been largely poorly investigated. cGvHD is a multi-organ 
autoimmune disorder and is the major cause of non-relapse morbidity and mortality 
following allo-HSCT, occurring in about 50% of patients, or 13,000–15,000 patients 
per year worldwide. Therefore, there is a high medical need for an early prediction of 
these therapy-associated toxicities. Biomarkers have gained importance over the last 
decade in diagnosis, in prognosis, and in prediction of pending diseases or side effects. 
Biomarkers can be cells, factors isolated from target tissues, or soluble factors that can 
be detected in body fluids. In this review, we aim to summarize some of the recent devel-
opments of biomarkers in the field of allo-HSCT. We will focus on cell-based biomarkers 
(B-cell subsets) for cGvHD and soluble factors including microRNA (miRNA), which are 
excreted into serum/plasma and urine. We also discuss the potential role of cytosolic and 
extracellular 70 kDa heat shock proteins (HSP70) as potential biomarkers for aGvHD and 
their role in preclinical models. Proteomic biomarkers in the blood have been used as 
predictors of treatment responses in patients with aGvHD for many years. More recently, 
miRNAs have been found to serve as a biomarker to diagnose aGvHD in the plasma. 
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COMPLiCATiONS OF HeMATOPOieTiC  
STeM CeLL TRANSPLANTATiON (HSCT)
Acute and chronic graft-versus-host disease (a/cGvHD) are seri-
ous and frequent complications after allogeneic hematopoietic 
stem cell transplantation (allo-HSCT) that negatively impact 
on survival and quality of life of patients (1, 2). GvHD develops 
in approximately 40–60% of recipients after allo-HSCT. Donor-
derived T-cells targeting alloantigens of the recipient play a key role 
in the induction of GvHD. Donor T-cells generally destroy host 
tissues by secreting pro-inflammatory cytokines such as interleu-
kin-1 (IL-1), tumor necrosis factor alpha (TNF-α), and interferon 
gamma (IFN-γ) or by direct cytolytic activities of immune effector 
cells (1, 2). So far, GvHD is diagnosed based on unique diagnostic 
clinical signs and symptoms, as recommended by the National 
Institutes of Health (NIH) consensus development conferences 
(3, 4). In 2014, the NIH Consensus Conference updated require-
ments for the integration of assessment of potential biomarkers in 
prospective clinical studies of GvHD (4). Biomarkers that could 
be obtained by minimal invasive methods would be beneficial to 
predict GvHD and thus would increase safety and quality of life 
of patients. Biomarkers should fulfill certain requirements such 
as the confirmation of an aGvHD or cGvHD, objectively measure 
disease activity, allow a distinction of organ damage, should pro-
vide prognostic risk assessment, and predict responses to therapy 
(5). Detailed documentations on collection of specimens includ-
ing excellent clinical data on patient characteristics and HSCT 
course, and standardized data analyses are crucial for further data 
processing (5). cGvHD is a multi-organ autoimmune disorder 
and is the major cause of non-relapse morbidity and mortality 
following allo-HSCT, occurring in about 50% of patients, or 
13,000–15,000 patients per year worldwide that causes a plethora 
of comorbidities including cardiovascular, gastrointestinal (GI), 
liver, pulmonary, endocrine (diabetes, hyperlipidemia, thyroid 
and adrenal insufficiency, hypogonadism), neuropsychiatric (e.g., 
depression, chronic neurologic diseases), bone and joint (osteo-
arthritis, osteoporosis) disorders, infections (bacterial, viral, and 
fungal), and other more specific comorbidities (solid malignancy, 
obesity, and infertility) (1–5). Herein, we discuss B-cell-based, 
stress protein-, and microRNA (miRNA)-based biomarkers as 
predictors for a/cGvHD.
CeLLULAR BiOMARKeRS
The Role of T/B-Cells As Cellular 
Biomarkers in cGvHD
For a long time it has been known that cross-reactive allo-T cells 
that were immunized by environmental antigens derived from 
the donor are key players in the induction of GvHD. Therefore, 
the determination of these cells and the measurement of their 
cytolytic activities against host tissues have been used to deter-
mine GvHD (6). The outcome of haploidentical HSCT can 
be improved by the depletion of T cells from the donor graft. 
However, this procedure is often accompanied by graft failure 
and an increased incidence of GvHD, which could be overcome 
by megadose HSCT, injecting of pathogen-specific T cells to 
rebuild immunity or engineered T cells to induce suicide in 
case of allo-reactivity (7). The sequential infusion of regulatory 
T cells (Tregs) (CD4+/CD25+ and CD4+/CD25−) after HSCT, 
the selective ex vivo (photo) depletion of certain autoreactive T 
cell clones, the preservation of γ/δ T cells in the stem cell graft, 
and the selection of the best stem cells provide other options to 
improve GVL effects while GvHD is not increased (7). All these 
procedures contribute to fewer infection and toxicity rates and 
leukemia-related death cases.
Recent research has demonstrated that apart from T cells, 
B-cells also play key roles in the pathogenesis of cGvHD. Therefore, 
the presence of auto- and alloantibodies, elevated plasma levels of 
B-cell activation factor (BAFF), a cytokine of the tumor necrosis 
family, and an accumulation of CD19+CD21low B-cells serve 
as biomarkers for GvHD. Apart from the depletion of T-cells 
by antibodies, the depletion of certain B-cell subpopulations 
might also provide a promising strategy to avoid GvHD (8–10). 
A delayed B-cell reconstitution with relative B-cell lymphopenia 
can result in downregulated B-cell counts in patients after HSCT 
(9–12). Low B-cell counts in the circulation may be explained 
in part by the insufficient production of B-cells in the bone 
marrow, as previously reported in patients with both, aGvHD 
and cGvHD (13). In contrast, a dysregulated B-cell homeostasis 
with persistent high BAFF levels can induce an upregulation of 
certain subpopulations of B-cells. In patients who do not develop 
cGvHD, elevated BAFF levels normalize after 6 months, whereas 
these remain highly elevated in patients developing cGvHD at 
later time points (11, 12). The observed high BAFF/B-cell ratio 
in patients with cGvHD suggests that during B-cell deficiency, 
autoreactive B-cell clones that would otherwise undergo nega-
tive selection could potentially survive due to an excess of BAFF, 
which in turn could possibly contribute to the pathophysiology of 
cGvHD (14–16). Furthermore, increased B-cell activation, aber-
rant B-cell signaling, and prolonged survival of activated B-cells 
have been found to be associated with cGvHD (17).
Perturbation of B-cell homeostasis can be associated with 
elevated or decreased numbers of different B-cell subpopulations 
during cGvHD (8, 11, 12, 16, 18, 19). Greinix and colleagues 
reported on elevated relative numbers of CD19+CD21low B-cells in 
patients with active cGvHD compared to those without cGvHD in 
Another development relates to urine-based biomarkers that are usually detected by 
capillary electrophoresis and mass spectrometry. These biomarkers have the potential 
to predict the development of severe aGvHD (grades III–IV), overall mortality, and the 
pending development of cGvHD in patients posttransplant.
Keywords: biomarkers, graft-versus-host disease, proteomics, genomics, cellular, heat shock protein, B-cell 
subsets
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a retrospective study on 70 patients (8). In addition, CD19+CD21low 
B-cell counts higher than 15% in patients with active cGvHD were 
found to be significantly associated with the presence of severe 
opportunistic infections (8). Furthermore, the memory B-cell 
compartment showed significantly lower relative and absolute 
numbers of both, non-class-switched CD19+CD27+IgD+ and 
class-switched CD19+CD27+IgD− memory B-cells. This observed 
perturbation of circulating B-cell subpopulations could be useful 
for assessing cGvHD activity and for identifying cGvHD patients 
at risk for severe infectious complications (8).
Kuzmina and colleagues investigated whether the number 
of CD19+CD21low B-cells could predict the outcome of extra-
corporeal photopheresis (ECP), which is used as one option 
for an immunomodulatory treatment of cGvHD (19). ECP 
non-responders had significantly higher (p = 0.02) relative num-
bers of CD19+CD21low B-cells (mean =  22%) in the peripheral 
blood prior to the start of ECP compared to patients achieving 
a complete response (CR) (mean =  8%) and partial response 
(mean = 16%) after 6 months of ECP therapy. These data suggest 
that CD19+CD21low B-cell counts could serve as a predictive cel-
lular biomarker. Moreover, CR patients had significantly lower 
relative numbers of CD19+CD21low B-cells 6, 12, and 21 months 
after start of ECP compared to non-responders, confirming that 
CD19+CD21low B-cells could be potential cellular biomarkers for 
objective response assessment in cGvHD (19).
CD19+CD21low B-cells were further investigated in cGvHD 
patient cohorts in the context of impaired humoral immunity 
defined by increased or decreased serum immunoglobulin G 
(IgG) levels (11). cGvHD patients with hypogammaglobulinemia 
had significantly decreased absolute numbers of CD19+ B-cells 
with elevated percentages of CD19+CD21low B-cells and tran-
sitional CD19+CD21int-highCD38highIgMhigh B-cells compared to 
cGvHD cohorts with normogammaglobulinemia or hypergam-
maglobulinemia, respectively. Furthermore, cGvHD patients 
with hypogammaglobulinemia also had a significant reduction 
of non-class-switched CD19+CD27+IgD+ and class-switched 
CD19+CD27+IgD− memory B-cells compared to the other two 
cohorts. Of note, cGvHD patients with hypergammaglobu-
linemia presented with significantly higher BAFF/B-cell ratios 
and frequently had significantly more autoantibodies present 
compared to the hypogammaglobulinemia cohort (11). Taken 
together, these data suggested that B-cell subpopulations could 
indicate different pathogenic mechanisms involved in cGvHD 
and might allow a distinction between immunodeficiency and 
autoimmunity (11, 16).
Investigation of B-cell subpopulations in the context of specific 
organ involvement by cGvHD revealed significantly decreased 
absolute and relative numbers of CD19+ B-cells in patients with 
newly diagnosed lung involvement seen as bronchiolitis oblit-
erans syndrome (BOS) (4, 16). The prognosis of BOS is poor, 
and therefore, the identification of patients at an early disease 
stage when they may have an improved response to immuno-
suppressive therapy is a major clinical challenge. Kuzmina and 
colleagues observed that patients with newly diagnosed BOS 
had significantly increased relative numbers of CD19+CD21low 
B-cells (25.5 versus 6.6%, p <  0.0001) and BAFF/CD19+ ratio 
(0.18 versus 0.02  ng/103 CD19+ B-cells, p =  0.007) compared 
with patients without cGvHD (16). Asymptomatic patients with 
a drop in pulmonary function tests and NIH-defined changes in 
high-resolution CT scan could be distinguished from patients 
without cGvHD due to significantly higher CD19+CD21low 
B-cells and ratio of BAFF/CD19+ B-cells. Interestingly, relative 
numbers of CD19+CD21low B-cells were significantly elevated 
both at onset of BOS as well as in patients with long-lasting BOS 
not responding to immunosuppressive treatment confirming a 
role of CD19+CD21low B-cells as cellular biomarkers for objective 
diagnosis of lung involvement as well as continued cGvHD activ-
ity during the course of therapy.
In a large prospective study with 227 patients, Greinix and 
colleagues performed serial analyses starting on day 100 after 
HSCT to investigate CD19+CD21low B-cells as diagnostic and 
predictive cellular biomarkers in patients with newly diagnosed 
cGvHD (18). Higher relative numbers of CD19+CD21low B-cells, 
analyzed on day 100 after HSCT and compared to time-matched 
controls without cGvHD, were significantly associated with later 
development of cGvHD independently of clinical parameters 
(23.5 versus 15.2%, p = 0.004). Furthermore, significantly higher 
percentages of CD19+CD21low B-cells were also associated with 
first diagnosis of cGvHD (18.3 versus 9.9%, p =  0.001) (18). 
Although their exact biological functions still need to be elu-
cidated, it is known that CD19+CD21low B-cells express inflam-
matory tissue-homing receptors, such as CXCR3 reflecting an 
increased capacity to home to inflammatory sites (20). Suryani 
and colleagues reported the production of significantly higher 
amounts of anti-nuclear autoantibodies by CD19+CD21low 
B-cells compared to other B-cell subpopulations such as naïve 
CD19+CD10−CD21highCD27− and memory CD19+CD27+IgD− 
B-cells, respectively (21). However, recent findings suggest that 
CD19+CD21low B-cells share the phenotype of anergic B-cells 
and do not proliferate in response to normal B-cell stimulation 
factors (22, 23).
Recently, regulatory B-cells (Bregs) have been shown to be 
involved in the pathogenesis of cGvHD (22, 24). Khoder and 
colleagues reported an enrichment of interleukin-10 (IL-10)-
producing Bregs within memory CD19+IgM+CD27+ and 
transitional CD19+CD24hiCD38hi B-cells in healthy individu-
als (25). In patients with cGvHD, Breg cells were found to be 
decreased and thus less likely to produce IL-10 compared to 
healthy donors and patients without cGvHD (25). Another 
study reported a decrease of CD24hiCD27+ B-cells and IL-10-
producing CD24hiCD27+ B-cells in patients with active cGvHD 
(26). Moreover, de Masson and colleagues observed increased 
CD24−CD38hi plasmablast frequencies, but decreased IL-10-
producing plasmablasts in patients with active cGvHD com-
pared to ones without cGvHD (22). Since CD24hiCD27+ B-cells 
and plasmablasts are among the most elevated cellular subsets 
within the Breg cell compartment, these observations could 
further support a possible role of Breg cells in the pathogenesis 
of cGvHD (22). Whether these novel cellular subpopulations 
could serve as biomarkers of active cGvHD, however, has to 
await further studies on well-defined patient cohorts including 
time-matched controls without cGvHD.
CD4+CD25+Foxp3+ Tregs have an indispensable role in the 
maintenance of tolerance after allo-HSCT. Poor reconstitution 
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of Tregs after HSCT correlated with subsequent development of 
cGvHD (27–29). Furthermore, patients with long-lasting cGvHD 
are known to have a deficiency of Tregs in the circulation (26, 
27). These findings led to therapeutic interventions aiming at 
enhancing Treg cell numbers by administration of low-dose 
interleukin-2 and thus, suppressing clinical manifestations of 
cGvHD (26). Based on these results, Tregs can be considered to 
be diagnostic and predictive cellular biomarkers of cGvHD.
Regarding other T-cell subpopulations, an increase in 
CCR7−CD45RA+CD8 T-cells that are effector memory T-cells 
and a decrease of CCR7+CD45RA+ naïve T-cells as well as 
CCR7+CD45RA− central memory T-cells has been reported 
in patients with cGvHD (30). The authors speculated whether 
their findings were the consequence of prolonged alloantigen 
exposure or interleukin-15 (IL-15) stimulation since patients 
with cGvHD reportedly have elevated IL-15 levels and effector 
memory T-cells can be generated by IL-15 stimulation. Yamashita 
and colleagues also observed a significantly higher percentage of 
CCR7−CD62LlowCD4+ effector memory T-cells in patients with 
cGvHD compared to ones without cGvHD or healthy donors 
(31). Furthermore, a preponderance of effector memory CD4+ 
T-cells relative to CCR7+CD45RA− central memory T-cells was 
observed in severe cGvHD by these investigators. In view of the 
small patient numbers in these single-center studies, confirma-
tion and validation of these findings is required prior to using 
these T-cell subpopulations as diagnostic cellular biomarkers of 
cGvHD.
Greinix and colleagues recently reported that CD4+CD45RA+ 
naïve T-cells and CD4+CD45RA+CD31+ T-cells were significantly 
increased in patients with newly diagnosed cGvHD compared to a 
time-matched patient cohort without cGvHD (18). Furthermore, 
this T-cell subset when measured prospectively on day +100 after 
HSCT was also significantly elevated in patients subsequently 
developing cGvHD compared to patients never experiencing 
cGvHD. Besides these T-cell subpopulations, CD3+CD56+ NKT 
cells were significantly increased on day +100 after HSCT in 
patients subsequently developing cGvHD and thus, could also 
serve as a predictive cellular biomarker.
SOLUBLe BiOMARKeRS
70-kDa Heat Shock Protein Family (HSP70) 
As a Biomarker for Tumors and GvHD
Members of the HSP70 family are known to play an important 
role in transport, folding, and unfolding of proteins and also in 
the induction of immune responses (32–38). The major stress-
inducible Hsp70 has been found to be upregulated in many 
different diseases including inflammation, autoimmunity, and 
tumors (32, 39). Hsp70 is also found on the cell surface of many 
tumor types including leukemic cells via a tumor-specific lipid 
anchorage (40). Furthermore, it was shown that membrane Hsp70 
positive, viable tumor cells are able to secrete Hsp70 into the 
circulation in lipid vesicles, termed exosomes (33, 41). Therefore, 
exosomal Hsp70 serves as a tumor-specific biomarker for viable 
tumor mass (42). Functionally, extracellular HSPs, either alone 
or in combination with antigenic peptides, play important roles 
in the induction of inflammatory immune responses (34, 35, 43, 
44). Apart from lipid-bound Hsp70, Hsp70 can be released by 
necrotic and inflamed tissues as a free molecule. This means that 
the major stress-inducible Hsp70 is secreted into the circulation 
either by living tumor cells in lipid vesicles, presumably tumor 
exosomes (41), or as a free molecule by dying necrotic and/or 
inflamed tissues. In cGvHD, inflammatory responses can occur 
in skin (77%), lung (50%), mouth (63%), liver (58%), eye (54%), 
joints (32%), GI (20%), and genital tract (16%). Therefore, free 
Hsp70, antibodies directed against Hsp70, mRNA levels might 
provide potential novel molecular biomarkers to diagnose and 
predict the onset of inflammation in cGvHD. Apart from mem-
bers of the HSP70 family other stress proteins are discussed as 
potential markers for GvHD.
In a rat skin explant model, Novota et al could demonstrate 
that the two major stress-inducible genes Hsp70-1 and Hsp70-2 
were upregulated. Therefore, elevated mRNA levels were associ-
ated with the grade of graft-versus-host reactions (GvHR) (45). 
Moreover, in the study by Kim et al., it was shown that a polymor-
phism in Hsp70-hom plays an important role in the prognosis 
of patients who received a sibling HLA-matched allo-HSCT 
(46). Thus, Hsp70-hom gene polymorphism might also serve 
as a prognostic marker for GvHD (47). A subsequent study by 
Bogunia-Kubik et al showed that patients who were homozygous 
for the A allele of the Hsp70-hom +2,663 SNP presented more 
frequently with grade II and IV toxic lesions and aGvHD com-
pared to patients with different genotypes (48).
Other studies clearly demonstrated an involvement of the 
Hsp70 protein levels in the pathogenesis of GvHD. In a rat 
GvHD model that was induced by the injection of DA parental 
lymphoid cells into irradiated (LEW × DA)F1 rats, it was shown 
that the expression levels of Hsp70 were significantly increased 
in spleen and lymph nodes 7 and 14 days after induction of the 
disease (49). At later time points of the disease, the Hsp70 levels 
dropped to levels that were comparable to that of untreated 
control animals.
Different results exist with respect to HSP70-specific anti-
bodies in the circulation in a rat model and human patients. In a 
rat model, elevated levels of antibodies (IgM, IgG2a, and IgG2b) 
directed against HSP70 have been found to be associated with the 
onset of symptoms that were associated with the development 
of GvHD (50), whereas in pediatric patients, this association 
was not detected after allo-HSCT (51). In subsequent human 
studies however, elevated anti-HSP70 and anti-HSP90 antibody 
levels were found to be associated with the development of a/
cGvHD (52).
An association of the severity of GvHD disease and the expres-
sion of Hsp70 might be explained by the immunomodulatory 
activity of Hsp70. To date, several studies reported an involve-
ment of Hsp70 in the production of pro-inflammatory cytokines 
such as TNF-α, IL-1, IL-6, and IL-12 and the secretion of nitric 
oxide (NO) and C-C chemokines by dendritic cells, monocytes, 
and macrophages (53, 54). Moreover, Hsp70 can activate 
intracellular signaling cascades that influence immunoregula-
tory functions of immune cells through binding of either free 
or lipid-bound Hsp70 to specific cell surface receptors such as 
Toll-like receptors 2 and 4 (TLR2/4), scavenger receptor CD36, 
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low-density lipoprotein receptor-related protein CD91, C-type 
lectin receptor LOX-1, scavenger receptor SR-A, and CD40 (35). 
Through the induction of pro-inflammatory cytokines, Hsp70 
contributes to the pathogenesis of autoimmune and various 
chronic inflammatory diseases (55–58). Thus, Hsp70 can serve 
as a damage-associated molecular pattern that activates the host’s 
adaptive and innate immune system by initiating alloimmunity 
(59). Another mechanism of the immunoregulatory activity 
of Hsp70 is based on its peptide-binding capacity. Exogenous 
Hsp70 can chaperone and cross-present antigens and cargo them 
to the antigen-presenting cells and thus elicit adaptive immune 
responses (44, 60). Therefore, it is not too surprising that Hsp70 
is frequently upregulated in allografts, which in turn results in the 
progression of disease and allograft rejection (61–63).
Presumably, the modulation of Hsp70 levels might provide 
a therapeutic option for improving the outcome of GvHD. 
Previously, Oh et  al  showed, in a skin graft model, in which 
Hsp70 (Hsp70.1 gene) knock-out (KO) mice were used either as 
a donor or recipient, the importance of Hsp70 in acute allograft 
rejection (64). Allogeneic cells derived from Hsp70 KO mice 
were shown to induce lower rejection rates in recipients than 
those of Hsp70 wild-type animals. Therefore, the application of 
reagents that are able to silence Hsp70 expression may provide a 
promising strategy to reduce the risk for GvHD. The reduction 
of HSP70 levels by the administration of 15-deoxyspergualin 
(DSG), an immunosuppressive agent that binds to a consti-
tutively expressed member of the 70-kDa heat shock protein 
family, has been shown to significantly reduce GvHD-associated 
mortality (65). DSG treatment reduced HSP70 levels in spleen 
and lymph nodes, inhibited the anti-HSP70 antibody produc-
tion, and reduced the serum levels of IL-2, IFN-γ, TNF-α, and 
IL-10 (64).
In conclusion, monitoring levels of HSP70 protein and/or 
anti-HSP70 antibody levels in the serum after HSCT might serve 
as a diagnostic tool to predict the onset of GvHD. In addition, 
genetic or pharmacological modulation of the HSP70 expression 
may have a therapeutic potential in the treatment of GvHD.
Protein Markers in Body Fluids for 
Diagnosis of aGvHD
Serum, plasma (66–68), and saliva have been analyzed for pre-
diction or diagnosis of aGvHD and cGvHD (69–71). A surface-
enhanced laser desorption/ionization (SELDI) mass spectrometer 
was used to analyze plasma/serum in patients with and without 
GvHD post-HSCT by the group of Barrett in 2006 at the National 
Heart, Lung, and Blood Institute, National Institute of Health 
(NIH). They used SELDI to identify proteins/peptides differen-
tially excreted into plasma (69–71). Another group from the NIH 
analyzed salvia samples using SELDI, no further data have been 
reported for either study. Therefore, plasma proteomics may be a 
more promising approach. The group of Ferrara and colleagues 
have intensively studied the serum/plasma proteomic approach 
using enzyme-linked immunosorbent assays to detect the pres-
ence of several proteins in the serum/plasma of patients post 
allo-HSCT (66–68). Among other markers, they have described 
plasma markers for GI aGvHD (68), regenerating islet-derived 
protein 3a (Reg-3a) and suppression of tumorigenicity (ST2) as 
diagnostic markers for aGvHD and survival after HSCT. Reg-3a 
was tested in samples from 1,014 HSCT patients from three 
transplantation centers and Reg3a concentrations were threefold 
higher in patients at onset of GI GvHD than in all other patients 
and correlated with lower GI GvHD. Reg3a concentrations at 
time of GvHD onset predicted response to therapy at 4 weeks, 
1-year NRM, and 1-year survival (p ≤ 0.001). In a multivariate 
analysis, advanced clinical stage, severe histologic damage, and 
high Reg3α concentrations at GvHD diagnosis independently 
predicted 1-year NRM. The combination of Reg3a with clinical 
stage and histologic grade of GvHD can be used to improve risk 
stratification of patients.
The described biomarkers have been tested in two different 
centers (67, 68). To fulfill the criteria of a reliable biomarker, 
the biomarkers have to be defined in a test set, confirmed in a 
first validation set and then validated in a multicenter validation 
trial (5), as biomarkers need to be robust under different clinical 
conditions and prophylaxis strategies.
The group of Levine and Ferrara has recently achieved this 
goal for the so-called Ann Arbor Score of aGvHD, which relies 
on three biomarkers (Reg3 alpha, ST2, and sTNFR1). If this score 
is high at the time of onset of GvHD, it strongly predicts day 28 
treatment response and 6-month NRM irrespective of center-
specific strategies (72).
An international Mount Sinai Acute GvHD International 
Consortium (MAGIC consortium) has been recently founded, 
which prospectively monitors clinical data and samples from 
more than 1,000 pts receiving allogeneic SCT/year and now 
allows to develop biomarker score-based treatment stratification 
at the time of onset of GvHD (73).
None of the serum/plasma markers described to date can pre-
dict aGvHD development, but they can help to diagnose aGvHD, 
especially GI aGvHD and to define prognosis at a very early time 
point where clinical presentation fails to allow exact prediction. 
Earlier biomarker scores (e.g., at day 7) after HSCT are currently 
developed and hopefully will allow stratification of preemptive 
treatment in the future. Taken together, the proteomic monitor-
ing of patients holds promise for early diagnosis as well as risk 
stratification of patients.
Serum/plasma biomarker development for cGvHD is yet not 
at the state of prospective multicenter monitoring. Chemokine 
(C-X-C motif) ligand 9 (CXCL9), suppression of tumorigenicity 
2 (ST2), osteopontin, and soluble BAFF levels are candidates 
among others (74–77). In particular, recent work by Yu et al has 
described a biomarker panel for cGvHD using quantitative 
proteomic profiling by high-resolution tandem mass spectrom-
etry. Pooled plasma from patients with and without cGvHD at 
matched time points posttransplant were tested in a discovery set 
and two independent validation cohorts.
The matrix metalloproteinase 3 (MMP3) in the plasma cor-
relates with BOS, a serious complication after allo-HSCT. An 
area under the receiver-operating characteristic (ROC) curve for 
MMP3 indicated a value of 0.77 (78).
Another biomarker that may be linked to cGvHD or to the 
maintenance of remission is the presence of H-Y specific anti-
bodies that relate to a minor antigen mismatch. These antibodies 
appear approximately 4–12 months after HSCT predominantly 
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in male patients who were transplanted with female donor grafts. 
In the presence of alloantibodies, the cumulative incidence of 
cGvHD reached 89% at 5 years after HSCT compared with only 
31% in the absence of H-Y antibodies. However, the cumulative 
incidence of relapse reached 48% at 5 years in the absence of H-Y 
antibodies compared with 0% in the presence of H-Y alloanti-
bodies. Therefore, the authors concluded that antibody responses 
to H-Y antigens were associated with maintenance of disease 
remission in gender-mismatched HSCT. In a follow-up research 
project, the same group demonstrated that H-Y antigen-binding 
B-cells developed in male recipients of female hematopoietic cells 
that were associated with cGvHD (79). Of note, B-cells specific for 
the dominant H-Y epitope, DEAD box protein (DBY-2) appeared 
in significantly higher frequency in the circulation 6  months 
after HSCT in individuals who developed cGvHD later and thus, 
may predict cGvHD (79, 80). However, this single center study 
requires validation in larger prospective clinical studies to allow 
firm conclusions.
Biofluid miRNAs As Biomarkers for  
Graft-versus-Host Disease
Within the last decade, circulating short single-stranded miRNA 
has been identified in human plasma, serum, and also in urine 
(81, 82). Interestingly, these miRNAs were found to be resistant to 
RNase, boiling, changes in pH, extended storage, and freeze-thaw 
cycles (83). Functionally, miRNA molecules are considered as one 
of the major groups of translational regulators with the ability to 
regulate differentiation of blood cells and immune functions (84, 
85). The stability of miRNA in the circulation can be attributed 
to three major RNase protection mechanisms: miRNAs can be 
bound to protective proteins, such as nucleophosmin 1 (NPM1) 
and/or Agonaute 2 (Ago2) (86–88), miRNA can form complexes 
with lipid or lipoproteins including high-density lipoprotein 
and low-density lipoprotein, and miRNA can be encapsulated 
in extracellular lipid vesicles, such as exosomes (89, 90). The 
complex of miRNA and these proteins and/or vesicles allows 
the selective export of miRNAs into the circulation and the 
protection of them within the extracellular environment (86). 
Circulating miRNAs have been shown to act as robust biomarkers 
for a various diseases, including autoimmune conditions, such 
as rheumatoid arthritis and systemic lupus erythematosus and 
tumors (91). A number of studies have also assessed the associa-
tion between circulating miRNAs and the development of GvHD, 
with promising results (92–96).
Circulating miRNAs are robust and can be detected in 
biofluids by minimal invasive methods using relatively simple 
and accurate technologies. Furthermore, circulating miRNAs 
may offer advantages over protein-based biomarkers as they are 
lower in complexity, conserved among clinically relevant species, 
expressed specifically in different tissues or biological stages and 
easily measured using common laboratory techniques (97).
Although miRNA studies in relation to GvHD are still in their 
infancy, miRNA-155 was the first miRNA to be associated with 
aGvHD (98). miRNA-155 expression is upregulated in T cells 
of mice with severe aGvHD after allo-HSCT and a reduction 
of miRNA-155 results in a decreased severity of aGvHD and a 
prolonged survival of mice (99). miRNA-155 is encoded within 
the B cell integration cluster and is important for the regulation 
of acute inflammation and innate immunity (98). Expression of 
miRNA-155 can be activated by inflammatory mediators, such 
as IFN-α/γ and TNF-α (100), and Ceppi et  al proposed that it 
functions as part of the negative feedback loop controlling 
the secretion of inflammatory cytokines by LPS-induced DC 
activation (101). Thus, miRNA-155 is pivotal in fine-tuning of 
the immune response (Figure 1). Physiologically, miRNA-155 is 
upregulated during T cell differentiation, plays a role in CD4+ 
and CD8+ T cell-mediated immunity and promotes the develop-
ment of T cells, including Th17 and Treg subsets. Mice with a 
germ-line depletion of miRNA-155 have a normal lymphocyte 
development but defective T and B cell immunity (102, 103). 
Within Tregs, miRNA-155 targets forkhead box P3 (FoxP3), 
which regulates in  vivo Treg survival (104). miRNA-155 also 
directly targets the IL-2 signaling protein suppressor of cytokine 
signaling 1 (SOCS1), whereby miRNA-155 deficiency in Tregs 
results in increased SOCS1 expression (96). This, in turn, leads 
to impaired activation of signal transducer and activator of 
transcription factor 5 (STAT5) phosphorylation and IL-2 recep-
tor signaling (105). miRNA-155 is also a key regulator of CD8+ 
T cell responses via SOCS1, where a deficiency of miRNA-155 
results in defective STAT5-mediated cytokine signaling (106). 
In CD4+ T  cells,  miRNA-155 targets phosphatidylinositol 
3,4,5-triphosphate 5-phosphatase 1 (SHIP1) for downregulation, 
which normally functions to suppress Th1 responses and T cells 
by modulating IFN-γ production (102, 107).
In a seminal study in 2012, Ranganathan et  al  showed that 
miRNA-155 is upregulated in T-cells from mice developing 
GvHD following HSCT (98). Moreover, the use of miRNA-155 
inhibitors decreased disease severity and prolonging survival (98). 
In addition, the group found increased miRNA-155 expression in 
small and large bowel biopsies compared to normal bowel tissue 
in patients with GI aGvHD (98). However, these studies focused 
on miRNA expression within tissue biopsies, and more recently, 
several groups have sought to exploit the biomarker potential of 
circulating miRNAs in the context of GvHD. Although the pres-
ence of miRNAs has been established in a number of biological 
fluids (103), studies to date have concentrated on serum and 
plasma fractions of the blood.
A comprehensive report published by Xiao et al (92) in 2013 
used a high-throughput qRT-PCR-based array to profile the 
expression of 345 miRNAs in the plasma of patients with aGvHD 
compared to those with no GvHD. They employed a discovery 
and training cohort to identify a final signature of four miRNAs 
(miRNA-423, miRNA-199-3p, miRNA-93*, and miRNA-377). 
These four miRNAs were able to predict aGvHD 6 weeks post-
HSCT, prior to the onset of symptoms. The model was significant 
in ROC analysis (AUC = 0.76, p < 0.001) and was also associ-
ated with disease severity and poor overall survival (92). The 
miRNAs were shown to be specific for aGvHD, as they were not 
detected in the plasma of lung transplant or non-transplant sepsis 
patients. This study highlighted the potential of biofluid miRNAs 
as independent markers for prediction, prognosis, and diagnosis 
of GvHD.
Although miRNA-155 has been previously associated with the 
development of GvHD, it was not included in the final model 
FiGURe 1 | An upregulated expression of microRNA (miRNA)-155 in T-cells is indicative for lethal acute graft-versus-host disease (aGvHD) in mice. 
miR-155 plays a central role in fine-tuning the immune response, and expression can be triggered by T cell receptor (TCR) signaling. miRNA-155 regulates FOXP3, 
which is important for the survival of T regulatory cells and influences the targets signal transducer and activator of transcription factor 5 (STAT5) and suppressor of 
cytokine signaling 1 (SOCS1). Targeting of 3,4,5-triphosphate 5-phosphatase 1 (SHIP1) by miRNA-155 results in an increased T-cell survival by an upregulated 
production of IFN-γ (93, 104–108).
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proposed by Xiao et  al. While expression was significantly 
upregulated in the plasma of aGvHD patients, levels were the 
lowest among the miRNA candidates identified (92). However, 
a recent study by Xie et  al  focusing on serum showed that 
miRNA-155 was significantly upregulated in aGvHD patients 
(p = 0.003) and also correlated with disease severity (p < 0.001) 
(93). Furthermore, expression was elevated in cGvHD patients 
compared to those who did not develop the disease (p = 0.005); 
however, levels were not sufficient to distinguish between aGvHD 
and cGvHD (p = 0.96) (93). Although this study showed promise 
for the inclusion of miRNA-155 as a GvHD biofluid biomarker, 
the study was restricted to one cohort of Han Chinese population 
(n = 64). Thus, the results need to be validated in independent 
prospective cohorts.
A small study by Sang et al confirmed elevated miRNA-155 
plasma levels in patients with aGvHD, and additionally reported 
upregulation of miRNA-92b, while miRNA-150 and miRNA-181 
were significantly downregulated (95). Interestingly, levels of the 
miRNAs were also altered prior to disease onset, highlighting 
their biomarker potential for predicting incidence (95). However, 
the difference in miRNA-181 was most pronounced, with no vari-
ation observed in control patients compared to reduced levels of 
expression in 19/22 (86%) patients prior to disease development 
(95). The group also demonstrated miRNA-181 to act as an 
effective predictor of aGvHD in a murine allo-HSCT model (95); 
however, larger cohorts are required in order to validate these 
findings.
More recently, Wang et  al  performed a study focusing on 
miRNA-586 expression in the plasma of HSCT patients (96). 
miRNA-586 was significantly upregulated in patients who 
developed aGvHD compared to no aGvHD as early as 7  days 
post-HSCT; however, expression was influenced by infection 
that reduced the significance of the association (96). As infections 
are common in early post-HSCT and can make distinguishing a 
diagnosis of aGvHD more challenging, it is important to validate 
the findings in larger studies as well as to elucidate the biological 
role of miRNA-586 in infections. Thus, although these results 
shown promise, miRNA-586 may play a greater role as a clinical 
biomarker to differentiate aGvHD from infectious complications.
In a separate study, Gimondi et  al  focused on lymphoma 
patients receiving MUD allo-transplants to profile the plasma 
using qRT-PCR for global miRNA expression (94). Assessing 
samples collected 28  days post-HSCT, 113 miRNAs were 
detected in all samples and of these, 27 could collectively dis-
criminate between aGvHD versus no aGvHD and miRNA-194 
and miRNA-518f were significantly upregulated in the patients 
who later developed the disease (94). The authors did not detect 
differential expression of miRNAs identified by Xiao et al (92), 
and there was no validation cohort included in the investigation. 
Thus, although results showed potential for the identification of 
aGvHD biomarkers, additional confirmatory studies are required.
Although circulating miRNAs as biomarkers for GvHD show 
great promise, these studies are still in their infancy and few over-
lapping targets between reports have been identified. A summary 
of presently known miRNAs for a/cGvHD have been presented 
in Table  1. Much work is needed to validate the findings in 
independent cohorts that reflect the heterogeneity in condition-
ing and prophylaxis regimens employed by different clinical 
TABLe 1 | Role of different microRNAs (miRNAs) in acute and chronic 
graft-versus-host disease (a/cGvHD).
MicroRNA Findings Reference
miR-155 ↑ in bowel tissue in aGvHD (98)
miR-155 ↑ in plasma in aGvHD and cGvHD (93)
miR-155 ↑ in plasma in aGvHD (95)
miR-423 ↑ in plasma in aGvHD (92)
miR-199-3p ↑ in plasma in aGvHD (92)
miR-93* ↑ in plasma in aGvHD (92)
miR-377 ↑ in plasma in aGvHD (92)
miR-92b ↑ in plasma in aGvHD (95)
miR-150 ↓ in plasma in aGvHD (95)
miR-181 ↓ in plasma in aGvHD (95)
miR-586 ↑ in plasma in aGvHD (96)
miR-194 ↑ in plasma in aGvHD (94)
miR-518f ↑ in plasma in aGvHD (94)
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centers. Moreover, collaboration between groups will allow for 
the standardization of protocols and technologies, which may 
greatly influence the reproducibility of findings and is a likely 
explanation for the lack of concordance in results to date. For 
blood studies, the choice of serum or plasma needs to be consid-
ered, with slightly more biomarker studies currently focusing on 
serum over plasma, while few whole blood or PBMC studies have 
been performed (108). Indeed, it has been proposed that profiles 
from isolated PBMC may yield information on the immune sta-
tus of the disease, while the serum and plasma levels reflect the 
disease-dependent secretion and expression of miRNAs (108). 
The effect of hemolysis and platelet contamination as well as the 
choice of anti-coagulant should also be considered (109–111). 
Selection of the miRNA detection platform and normalization 
as well as the RNA isolation methodology employed has also 
been shown to affect results. Indeed, analytical variables have a 
huge potential to bias results, and this is particularly dependent 
on the normalization methods used (112). Some level of cor-
rection may be achieved by spiking in synthetic miRNAs (113); 
however, this approach can correct for technical variation such 
as the efficiency of RNA isolation and reverse transcription, but 
it will not account for intrinsic biological variation (114). Thus, 
the choice of normalization controls and/or global normalization 
becomes integral to the data analysis strategy. With regard to 
the miRNA detection platform, although qRT-PCR is a com-
monly used approach, variations on the fluorescent molecules 
including TaqMan and Sybr-Green, as well as the development 
of newer techniques including NanoString and Next-generation 
sequencing, have increased heterogeneity. This is important, as 
variation in results have been observed depending on the analysis 
platform, partly attributed to the difficulty in distinguishing small 
molecules at low abundance with high sequence homology (115).
Despite these considerations, it is expected that over the next 
few years, as the number of circulating miRNA biomarker studies 
increases, specific miRNA patterns for GvHD will be proposed 
and validated in the clinic. Although studies to date have focused 
on fractions of the blood, the potential for discovery of miRNA 
signatures in other fluids, including urine, is attractive. Indeed, 
initial data promise that miRNA signatures may be identified 
to predict the incidence of GvHD prior to onset, the severity of 
disease, to distinguish GvHD from other complications, and even 
to differentiate between aGvHD and cGvHD, particularly in rela-
tion to late onset aGvHD. Given the heterogeneity of transplan-
tation protocols employed throughout different clinics, miRNA 
models appropriate to different transplant protocols may also be 
possible. Further investigation of validated miRNA signatures will 
allow the impact of miRNA dysregulation on the pathogenesis of 
GvHD to be studied, and conclusively, prospective investigations 
assessing the outcome of treatments selected by miRNA status 
will confirm their prognostic strength. Ultimately, the aim will be 
to diagnose GvHD and outcome before clinical symptoms mani-
fest, allowing earlier introduction of therapy, tailored treatments, 
and reduced mortality and morbidity outcomes.
URiNe PROTeOMiCS BASeD ON 
CAPiLLARY eLeCTROPHOReSiS AND 
MASS SPeCTROMeTRY (Ce-MS)
Proteomics for Prediction of aGvHD after 
HSCT
Proteomics of tissues or body fluids has gained significant impor-
tance over the last 10 years.
For example, urinary proteome-based classifiers, developed 
for aGvHD prediction, were first described in 2004 (116) and 
adapted in 2007 (117) and additional prospective evaluation 
was provided in 2014 (118). The urinary proteome profiling for 
aGvHD is done on prospectively collected urine samples from 
patients undergoing HSCT. The urine is collected prior to HSCT 
and conditioning, weekly after HSCT until day +35 and afterward 
biweekly until day +100. Urine can be frozen at −20°C until 
preparation of the sample for analyses using CE-MS (119–122). 
An extension to include patients with cGvHD was carried out in 
2008; thus, samples were collected bimonthly after day +100 or 
at diagnosis of cGvHD (119, 123).
Acute and chronic GvHD are currently diagnosed on clinical 
parameters defined in NIH Consensus (2, 124, 125) and German 
Consensus Conferences (126–128). Prediction of aGvHD using 
the investigator-independent, unbiased proteomic classifier 
aGvHD_MS17 was done on more than 500 patients in at least 4 
centers in Germany and UK and resulted in stable prediction of 
aGvHD about 7–10 days prior to clinical diagnosis or biopsy posi-
tivity (118, 119, 123, 129). The classifier aGvHD_MS17 consists of 
17 peptides, 10 of which have been sequenced to date (117–119). 
The identified peptides are various fragments of collagen (indi-
cating disturbances in metabolism of collagen and/or early organ 
damage) and fragments of fibronectin, beta-2-microglobulin 
(β2M), and CD99, an activation marker of T-cells. Multivariate 
regression analysis showed that aGvHD_MS17 positivity was 
the highest predictive parameter for aGvHD development 
(p < 0.0001, Figure 2).
FUTURe PeRSPeCTiveS
Numerous candidates for biomarkers are currently available, 
which include plasma and serum markers, cell-based markers 
such as B-cell subpopulations, and T follicular helper cells 
FiGURe 2 | incidence of developing an acute graft-versus-host 
disease (aGvHD) grades ii–iv. Incidence of aGvHD grades II–IV is 
predicted by aGvHD_MS17 positivity (p = 0.0001) when compared to 
patients without aGvHD_MS17 pattern positivity. Shown is the percentage 
(%) of patients with aGvHD II–IV with (black line) or without aGvHD_MS17 
positivity over time [days after allogeneic hematopoietic stem cell 
transplantation (allo-HSCT)] (gray line).
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as regulators of B-cell immunity in determining cGvHD in 
patients (130), miRNAs, different stress proteins, or proteomic 
approaches using plasma, serum, or urine. Proteomic mass 
spectrometry analysis coupled with computational biology 
approaches will further lead to the identification of novel bio-
markers for GvHD such as BOS in the lung (131). Recently, the 
diversity of the intestinal microbiome as analyzed by 16 s rRNA 
sequencing of stool microbiota (131–134) and the assessment 
of bacterial metabolites (135) very early after transplantation 
has identified patients at high risk of lethal complications. On 
the other hand, biomarkers can also be used to tailor immuno-
suppressive therapies in transplanted patients and thus might 
predict the severity of GvHD.
The main challenge remains to integrate all these candidates 
and to validate them as biomarkers that are valid in multiple 
centers independent of the center’s strategy of prophylaxis, and 
consortia on prospective testing of these markers together with 
clinical data collection as shown for the MAGIC consortium are 
urgently needed. The expectations have to be defined clearly, do 
we want to predict outcome in general or treatment response for 
aGvHD or cGvHD or do we want to make a diagnosis as precise 
as possible (e.g., for GI GvHD, for cGvHD) and the current 
standards and endpoints for each of these parameters have to be 
defined separately (e.g., d28 response for aGvHD, 2- or 3-month 
response for cGvHD, 6  months NRM for aGvHD, composite 
endpoints of GvHD-free and relapse-free survivals) (136).
New candidates have to be integrated in this process step by 
step, and bio-mathematical approaches are needed to define those 
markers that give true additive information. In addition, integra-
tion of older markers has not been performed (e.g., calprotectin 
in stool samples for GI GvHD (137), the poor man’s biomarker 
albumin for GI GvHD) (138, 139), and more importantly, testing 
biomarkers against clinical predictors or markers of outcome is 
needed. For aGvHD, factors indicating poor prognosis are the 
extent of organ involvement and number of involved organs. For 
cGvHD, the type of onset and simultaneous occurrence of throm-
bocytopenia should be addressed. It might well be that some of 
the markers behave as highly sensitive and specific markers due 
to the correlation with extent and type of involved organ and the 
specific pathophysiology, which might be reflected by the correla-
tion with clinical parameters (140).
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